Company News
Phage Display Technology: Market Prospects and Research Advances
Phage Display Technology: Market Prospect Analysis And Research Progress
Literature Analysis| Dual CD47 and PD-L1 Blockade Boosts CD8+ T Cell Anti-Tumor Response
Literature Title: Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8+ T cells.
Literature Analysis | Novel VH3 Scaffold Library Boosts Single-Domain Antibody Stability
On July 31, 2024, in the journal Scientific Reports, Nam Ju Lee et al. published a paper titled A single domain antibody library based on a stability-engineered human VH3 scaffold.
Lasted News | Novel Nanobody Inhibitors Target Ebola Virus: Nanosota-EB1 & EB2
On December 23, 2024, Fan Bu et al. published a paper titled "Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection" in the journal PLOS Pathogens.
Accelerate Drug Discovery with Biosimilar Antibodies - The Fast Track to Target Binding
Alpha Lifetech's 700+ biosimilar antibodies target EGFR, TNF-α, VEGF, speeding up drug research with validated quality.
Unlocking the Mysteries of Biological Processes: Alpha Lifetech Produces High-Quality Membrane Proteins for Scientists
Alpha Lifetech offers quality membrane proteins for drug discovery and cellular insights, using advanced production techniques.
The Art and Science of Nanobody Discovery: How Alpha Lifetech is Pushing Boundaries
Discover nanobody technology: phage display, immunization, screening, selection, and structural analysis at Alpha Lifetech for diagnostics and therapy.